Resolvin D2 supports MCF-7 cell proliferation via activation of estrogen receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 1, 2014, Pages 172-180

  Al Zaubai, Nuha ^a   Johnstone, Cameron N ^a   Leong, May May ^b   Li, John ^b   Rizzacasa, Mark ^b   Stewart, Alastair G ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4',6 DIAMIDINO 2 PHENYLINDOLE; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; ICOSANOID; RESOLVIN D2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; UO 126; DOCOSAHEXAENOIC ACID; PROTEIN BINDING;

ARTICLE; BINDING SITE; CCND1 GENE; CELL COUNT; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE; GENE EXPRESSION; GREB1 GENE; IMMUNOREACTIVITY; IN VITRO STUDY; MCF 7 CELL LINE; NUCLEAR LOCALIZATION SIGNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TGF BETA 3 GENE; TGF BETA RII GENE; TRANSCRIPTION INITIATION; UPREGULATION; AGONISTS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HUMAN; METABOLISM;

CELL PROLIFERATION; DOCOSAHEXAENOIC ACIDS; ESTRADIOL; HUMANS; MCF-7 CELLS; PROTEIN BINDING; RECEPTORS, ESTROGEN;

EID: 84907168932     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.214403     Document Type: Article

References (44)

1. Arrick BA, Korc M, and Derynck R (1990) Differential regulation of expression of three transforming growth factor b species in human breast cancer cell lines by estradiol. Cancer Res 50:299-303.
2. Baumgarten SC and Frasor J (2012) Minireview: inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol 26:360-371.
3. Bonéy-Montoya J, Ziegler YS, Curtis CD, Montoya JA, and Nardulli AM (2010) Longrange transcriptional control of progesterone receptor gene expression. Mol Endocrinol 24:346-358.
4. Broselid S, Cheng B, Sjöström M, Lövgren K, Klug-De Santiago HLP, Belting M, Jirström K, Malmström P, Olde B, and Bendahl P-O, et al. (2013) G proteincoupled estrogen receptor is apoptotic and correlates with increased distant disease-free survival of estrogen receptor-positive breast cancer patients. Clin Cancer Res 19:1681-1692.
5. Bruunsgaard H, Pedersen M, and Pedersen BK (2001) Aging and proinflammatory cytokines. Curr Opin Hematol 8:131-136.
6. Bunone G, Briand PA, Miksicek RJ, and Picard D (1996) Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 15:2174-2183.
7. Casimiro MC, Velasco-Velázquez M, Aguirre-Alvarado C, and Pestell RG (2014) Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present. Expert Opin Investig Drugs 23:295-304.
8. Casimiro MC, Wang C, Li Z, Di Sante G, Willmart NE, Addya S, Chen L, Liu Y, Lisanti MP, and Pestell RG (2013) Cyclin D1 determines estrogen signaling in the mammary gland in vivo. Mol Endocrinol 27:1415-1428.
9. Castaneda CA, Cortes-Funes H, Gomez HL, and Ciruelos EM (2010) The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev 29:751-759.
10. Deschênes J, Bourdeau V, White JH, and Mader S (2007) Regulation of GREB1 transcription by estrogen receptor a through a multipartite enhancer spread over 20 kb of upstream flanking sequences. J Biol Chem 282:17335-17339.
11. Driggers PH and Segars JH (2002) Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol Metab 13:422-427.
12. Frasor J, Danes JM, Komm B, Chang KCN, Lyttle CR, and Katzenellenbogen BS (2003) Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144:4562-4574.
13. Gohno T, Seino Y, Hanamura T, Niwa T, Matsumoto M, Yaegashi N, Oba H, Kurosumi M, Takei H, and Yamaguchi Y, et al. (2012) Individual transcriptional activity of estrogen receptors in primary breast cancer and its clinical significance. Cancer Med 1:328-337.
14. Hall JM, Couse JF, and Korach KS (2001) The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276:36869-36872.
15. Hanahan D and Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674.
16. Hughes RA, Harris T, Altmann E, McAllister D, Vlahos R, Robertson A, Cushman M, Wang Z, and Stewart AG (2002) 2-Methoxyestradiol and analogs as novel antiproliferative agents: analysis of three-dimensional quantitative structure-activity relationships for DNA synthesis inhibition and estrogen receptor binding. Mol Pharmacol 61:1053-1069.
17. Ignar-Trowbridge DM, Pimentel M, Parker MG, McLachlan JA, and Korach KS (1996) Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 137:1735-1744.
18. Jacobs L and Finlayson CA(2011) Breast Cancer (Jacobs L, Finlayson CA, eds). Philadelphia: Saunders Elsevier.
19. Jiang WG, Douglas-Jones AG, and Mansel RE (2006a) Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer. Prostaglandins Leukot Essent Fatty Acids 74:125-134.
20. Jiang WG, Watkins G, Douglas-Jones A, and Mansel RE (2006b) Reduction of isoforms of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in human breast cancer. Prostaglandins Leukot Essent Fatty Acids 74:235-245.
21. Jiang X and Shapiro DJ (2014) The immune system and inflammation in breast cancer. Mol Cell Endocrinol.
22. Khau T, Langenbach SY, Schuliga M, Harris T, Johnstone CN, Anderson RL, and Stewart AG (2011) Annexin-1 signals mitogen-stimulated breast tumor cell proliferation by activation of the formyl peptide receptors (FPRs) 1 and 2. FASEB J 25:483-496.
23. Leclercq G, Lacroix M, Laïos I, and Laurent G (2006) Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells. Curr Cancer Drug Targets 6:39-64.
24. Lee JH and Lee MJ (2012) Emerging roles of the ubiquitin-proteasome system in the steroid receptor signaling. Arch Pharm Res 35:397-407.
25. Li J, Leong MM, Stewart A, and Rizzacasa MA (2013) Total synthesis of the endogenous inflammation resolving lipid resolvin D2 using a common lynchpin. Beilstein J Org Chem 9:2762-2766.
26. Márquez DC, Lee J, Lin T, and Pietras RJ (2001) Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor. Endocrine 16:73-81.
27. Mas E, Croft KD, Zahra P, Barden A, and Mori TA (2012) Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem 58:1476-1484.
28. Miyahara T, Runge S, Chatterjee A, Chen M, Mottola G, Fitzgerald JM, Serhan CN, and Conte MS (2013) D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB J 27: 2220-2232.
29. Ouchi N, Parker JL, Lugus JJ, and Walsh K (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11:85-97.
30. Peurala E, Koivunen P, Haapasaari KM, Bloigu R, and Jukkola-Vuorinen A (2013) The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Res 15:1-10.
31. Pfeilschifter J, Köditz R, Pfohl M, and Schatz H (2002) Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23:90-119.
32. Power RF, Mani SK, Codina J, Conneely OM, and O'Malley BW (1991) Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 254: 1636-1639.
33. Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM, and Lippman ME (2005) GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat 92:141-149.
34. Renoir J-M, Marsaud V, and Lazennec G (2013) Estrogen receptor signaling as a target for novel breast cancer therapeutics. Biochem Pharmacol 85:449-465.
35. Riby JE, Chang GHF, Firestone GL, and Bjeldanes LF (2000) Ligand-independent activation of estrogen receptor function by 3, 39-diindolylmethane in human breast cancer cells. Biochem Pharmacol 60:167-177.
36. Russell R, Gori I, Pellegrini C, Kumar R, Achtari C, and Canny GO (2011) Lipoxin A4 is a novel estrogen receptor modulator. FASEB J 25:4326-4337.
37. Serhan CN (2007) Resolution phase of inflammation: novel endogenous antiinflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 25:101-137.
38. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LAJ, Perretti M, Rossi AG, and Wallace JL (2007) Resolution of inflammation: state of the art, definitions and terms. FASEB J 21:325-332.
39. Serhan CN, Chiang N, and Van Dyke TE (2008) Resolving inflammation: dual antiinflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8:349-361.
40. Serhan CN and Petasis NA (2011) Resolvins and protectins in inflammation resolution. Chem Rev 111:5922-5943.
41. Smith CL, Nawaz Z, and O'Malley BW (1997) Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11:657-666.
42. Vadlakonda L, Pasupuleti M, and Pallu R (2013) Role of PI3K-AKT-mTOR and Wnt Signaling Pathways in Transition of G1-S Phase of Cell Cycle in Cancer Cells. Front Oncol 3:1-7.
43. Wang D, Hu L, Zhang G, Zhang L, and Chen C (2010) G protein-coupled receptor 30 in tumor development. Endocrine 38:29-37.
44. Zhang X, Tanaka K, Yan J, Li J, Peng D, Jiang Y, Yang Z, Barton MC, Wen H, and Shi X (2013) Regulation of estrogen receptor a by histone methyltransferase SMYD2-mediated protein methylation. Proc Natl Acad Sci USA 110:17284-17289.